Acorda Therapeutics announced that it has received notification from Nasdaq informing the company that as of June 20 it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450. Acorda is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq Global Select Market.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACOR: